Amydis Diagnostics Adds Veteran Drug Development Executive and Chief Medical Officer to Management Team

SAN DIEGO, May 17, 2017 (GLOBE NEWSWIRE) -- Amydis Diagnostics, Inc., a preclinical stage, privately-held pharmaceutical company developing proprietary chemistry and innovative approaches to detection of amyloid-related disorders such as Alzheimer’s disease, announced the addition of Scott A. Reines, M.D., Ph.D. to their executive team. Dr. Reines will serve as Chief Medical Officer and work alongside Dr. Richard D’Souza in driving the R&D platform through clinical trials.

“Amydis is fortunate to have Scott join our executive team. Dr. Reines has a unique blend of experience in neurology and ophthalmology and developing innovative branded products that make him an ideal fit for the Company,” said Stella Sarraf, Ph.D., Interim Chief Executive Officer and Founder of Amydis Diagnostics, Inc. “Dr. Reines will lead the clinical development of our lead program in Alzheimer’s as well as help build our pipeline”.

“I have had the pleasure of working with Scott when I was at Merck and am excited to be teamed up with him again,” said Franz Hefti, Ph.D., Board Member of Amydis. “He is a fantastic addition to the Amydis team.”

Dr. Reines is a research physician with broad drug development experience leading to the approval of new drugs in five different therapeutic areas including neurology and ophthalmology. Prior to Amydis, he has served in leading roles at Johnson & Johnson and Merck, and currently chairs a Data Safety Monitoring Board. As Senior Vice President for CNS, Pain and Translational Medicine at J&J, Dr. Reines oversaw the development and approval of numerous drugs for the treatment of schizophrenia, Alzheimer’s, pain and migraine headache. Prior to that, Dr. Reines served as Vice President, Clinical Research at Merck with responsibilities for Psychopharmacology, Neuropharmacology, Gastroenterology, and Ophthalmology. While there, he oversaw the conduct on one of the first large, multicenter trials for the prevention of Alzheimer’s disease and led the development of leading brand drugs for nausea and vomiting, migraine, Parkinson’s and glaucoma.

Dr. Reines served for two years as co-chair of the Neuroscience Steering Committee, Foundation for NIH Biomarkers Consortium, and spent five years on the National Drug Abuse Advisory Council. He holds a bachelor’s degree in chemistry from Cornell University, a doctoral degree in chemistry/molecular biology from Columbia University, and a medical degree from Albert Einstein College of Medicine. He is Board Certified in Psychiatry and Neurology.

About Amydis Diagnostics, Inc.

Amydis Diagnostics, Inc. was founded in 2013 to address the urgent medical and clinical need for more sensitive and specific diagnostic testing for Alzheimer’s disease. By significantly improving the effectiveness, accessibility, and ease of testing, our unique technology has the potential to help physicians detect Alzheimer’s disease at its earliest stages, and in doing so, allows appropriate therapeutic options to be developed or pursued. The power of knowing will enable patients and physicians to make the right decisions and change the lives of those impacted by the disease. More information on Amydis can be found at www.amydis.com.

Amydis Diagnostics Contact David H. Crean, Ph.D. Chief Business Officer Amydis Diagnostics, Inc. 3210 Merryfield Row San Diego, CA 92121 Tel: 858.707.5352 Email: david@amydis.com

Source:Amydis Diagnostics, Inc.